Sirolimus has “a much wider” safety window and shows fewer local effects than paclitaxel


“Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them,” says Peter Gaines (Sheffield, UK). Gaines commented at the 2019 Vascular Leaders Forum (VLF; 1–2 March, Washington, DC, USA) on the modes of action of these two agents that have been used in drug-coated devices in both the coronary and peripheral vessels. “Sirolimus is likely to have fewer systemic problems [than paclitaxel] and is much less likely to have local toxic effects on the arteries,” he says.


Please enter your comment!
Please enter your name here